{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:51:34Z","timestamp":1791888694175,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T00:00:00Z","timestamp":1527120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s11523-018-0571-4","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T00:59:10Z","timestamp":1527123550000},"page":"409-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Avelumab: A Review in Metastatic Merkel Cell Carcinoma"],"prefix":"10.1007","volume":"13","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,24]]},"reference":[{"key":"571_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejca.2016.10.022","volume":"71","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, Lebbe C, zur Hausen A, et al. Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer. 2017;71:53\u201369.","journal-title":"Eur J Cancer"},{"issue":"4","key":"571_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11154-017-9433-0","volume":"18","author":"T Amaral","year":"2017","unstructured":"Amaral T, Leiter U, Garbe C. Merkel cell carcinoma: epidemiology, pathogenesis, diagnosis and therapy. Rev Endocr Metab Disord. 2017;18(4):517\u201332.","journal-title":"Rev Endocr Metab Disord"},{"key":"571_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.77","volume":"3","author":"JC Becker","year":"2017","unstructured":"Becker JC, Stang A, DeCaprio JA, et al. Merkel cell carcinoma. Nat Rev Dis Primers. 2017;3:17077.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"571_CR4","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1245\/s10434-016-5266-4","volume":"23","author":"KL Harms","year":"2016","unstructured":"Harms KL, Healy MA, Nghiem P, et al. Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system. Ann Surg Oncol. 2016;23(11):3564\u201371.","journal-title":"Ann Surg Oncol"},{"key":"571_CR5","doi-asserted-by":"crossref","unstructured":"Cassler NM, Merrill D, Bichakjian CK, et al. Merkel cell carcinoma therapeutic update. Curr Treat Options in Oncol. 2016;17(36)","DOI":"10.1007\/s11864-016-0409-1"},{"key":"571_CR6","doi-asserted-by":"publisher","first-page":"327150","DOI":"10.1155\/2013\/327150","volume":"2013","author":"L Desch","year":"2013","unstructured":"Desch L, Kunstfeld R. Merkel cell carcinoma: chemotherapy and emerging new therapeutic options. J Skin Cancer. 2013;2013:327150.","journal-title":"J Skin Cancer"},{"issue":"16","key":"571_CR7","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/j.ejca.2015.06.131","volume":"51","author":"C Lebbe","year":"2015","unstructured":"Lebbe C, Becker JC, Grob J-J, et al. Diagnosis and treatment of Merkel cell carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(16):2396\u2013403.","journal-title":"Eur J Cancer"},{"key":"571_CR8","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae): Merkel cell carcinoma - version 1.2018. 2017. \n                    https:\/\/www.nccn.org\/\n                    \n                  . Accessed 20 Apr 2018."},{"issue":"14","key":"571_CR9","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2217\/fon-2017-0072","volume":"13","author":"P Nghiem","year":"2017","unstructured":"Nghiem P, Kaufman HL, Bharmal M, et al. Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol. 2017;13(14):1263\u201379.","journal-title":"Future Oncol"},{"issue":"3","key":"571_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/phar.1714","volume":"36","author":"PJ Medina","year":"2016","unstructured":"Medina PJ, Adams VR. PD-1 pathway inhibitors: immuno-oncology agents for restoring antitumor immune responses. Pharmacotherapy. 2016;36(3):317\u201334.","journal-title":"Pharmacotherapy"},{"key":"571_CR11","unstructured":"Webb ES, Liu P, Baleeiro R, et al. Immune checkpoint inhibitors in cancer therapy. J Biomed Res. 2017; \n                    http:\/\/journal.hep.com.cn\/jbr\/EN\/10.7555\/JBR.31.20160168#1\n                    \n                  ."},{"issue":"1","key":"571_CR12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/cancers5010234","volume":"5","author":"PL Triozzi","year":"2013","unstructured":"Triozzi PL, Fernandez AP. The role of the immune response in Merkel cell carcinoma. Cancers. 2013;5(1):234\u201354.","journal-title":"Cancers"},{"issue":"7","key":"571_CR13","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1093\/annonc\/mdx170","volume":"28","author":"K Chin","year":"2017","unstructured":"Chin K, Chand VK, Nuyten DSA. Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy. Ann Oncol. 2017;28(7):1658\u201366.","journal-title":"Ann Oncol"},{"issue":"1","key":"571_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2326-6066.CIR-13-0034","volume":"1","author":"EJ Lipson","year":"2013","unstructured":"Lipson EJ, Vincent JG, Loyo M, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013;1(1):54\u201363.","journal-title":"Cancer Immunol Res."},{"issue":"19","key":"571_CR15","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.1158\/1078-0432.CCR-13-0035","volume":"19","author":"OK Afanasiev","year":"2013","unstructured":"Afanasiev OK, Yelistratova L, Miller N, et al. Merkel polyomavirus-specific T cells fluctuate with Merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res. 2013;19(19):5351\u201360.","journal-title":"Clin Cancer Res"},{"key":"571_CR16","unstructured":"European Medicines Agency. Bavencio (avelumab): summary of product characteristics. 2018. \n                    http:\/\/www.ema.europa.eu\n                    \n                  . Accessed 20 Apr 2018."},{"key":"571_CR17","unstructured":"US FDA. Bavencio\u00ae (avelumab): US prescribing information. 2017. \n                    www.fda.gov\/\n                    \n                  . Accessed 20 Apr 2018."},{"key":"571_CR18","unstructured":"Pharmaceuticals and Medical Devices Agency (Japan). Bavencio\u00ae (avelumab): Japanese prescribing information. 2017. \n                    http:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/380079_4291438A1022_1_01\n                    \n                  . Accessed 30 Apr 2018."},{"issue":"5","key":"571_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","volume":"18","author":"CR Heery","year":"2017","unstructured":"Heery CR, O'Sullivan-Coyne G, Madan RA, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN solid tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18(5):587\u201398.","journal-title":"Lancet Oncol."},{"issue":"10","key":"571_CR20","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","volume":"3","author":"B Boyerinas","year":"2015","unstructured":"Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3(10):1148\u201357.","journal-title":"Cancer Immunol Res"},{"issue":"23","key":"571_CR21","doi-asserted-by":"publisher","first-page":"33498","DOI":"10.18632\/oncotarget.9256","volume":"7","author":"R Fujii","year":"2016","unstructured":"Fujii R, Friedman ER, Richards J, et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget. 2016;7(23):33498\u2013511.","journal-title":"Oncotarget"},{"issue":"5","key":"571_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.27","volume":"5","author":"I Grenga","year":"2016","unstructured":"Grenga I, Donahue RN, Lepone LM, et al. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunology. 2016;5(5):e83.","journal-title":"Clin Transl Immunology"},{"key":"571_CR23","unstructured":"European Medicines Agency. European public assessment report: Bavencio (avelumab). 2017. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/004338\/WC500236649.pdf\n                    \n                  . Accessed 20 Apr 2018."},{"key":"571_CR24","doi-asserted-by":"publisher","unstructured":"D'Angelo SP, Russell J, Lebb\u00e9 C, et al. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol. 2018; \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2018.0077\n                    \n                  .","DOI":"10.1001\/jamaoncol.2018.0077"},{"issue":"10","key":"571_CR25","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374\u201385.","journal-title":"Lancet Oncol"},{"issue":"1","key":"571_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40425-017-0310-x","volume":"6","author":"HL Kaufman","year":"2018","unstructured":"Kaufman HL, Russell JS, Hamid O, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after \u22651 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018;6(1):7.","journal-title":"J Immunother Cancer"},{"key":"571_CR27","doi-asserted-by":"crossref","unstructured":"D'Angelo SP, Russell JS, Bhatia S, et al. 18-month efficacy and safety update from JAVELIN Merkel 200 part A: a phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy [abstract no. 192 plus poster]. J Clin Oncol. 2018;36(Suppl 5S).","DOI":"10.1200\/JCO.2018.36.5_suppl.192"},{"key":"571_CR28","doi-asserted-by":"crossref","unstructured":"Kelly K, Infante JR, Taylor MH, et al. Safety profile of avelumab in patients with advanced solid tumors: a pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer. 2018;124(9):2010-17.","DOI":"10.1002\/cncr.31293"},{"key":"571_CR29","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2017.00730","volume":"8","author":"P-F Wang","year":"2017","unstructured":"Wang P-F, Chen Y, Song S-Y, et al. Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730.","journal-title":"Front Pharmacol"},{"issue":"19","key":"571_CR30","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.2217\/fon-2017-0187","volume":"13","author":"CL Cowey","year":"2017","unstructured":"Cowey CL, Mahnke L, Espirito J, et al. Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. Future Oncol. 2017;13(19):1699\u2013710.","journal-title":"Future Oncol"},{"issue":"45","key":"571_CR31","doi-asserted-by":"publisher","first-page":"79731","DOI":"10.18632\/oncotarget.19218","volume":"8","author":"JC Becker","year":"2017","unstructured":"Becker JC, Lorenz E, Ugurel S, et al. Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. Oncotarget. 2017;8(45):79731\u201341.","journal-title":"Oncotarget"},{"issue":"9","key":"571_CR32","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/cam4.815","volume":"5","author":"JG Iyer","year":"2016","unstructured":"Iyer JG, Blom A, Doumani R, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5(9):2294\u2013301.","journal-title":"Cancer Med"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-018-0571-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0571-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-018-0571-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T19:14:29Z","timestamp":1558638869000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-018-0571-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,24]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["571"],"URL":"https:\/\/doi.org\/10.1007\/s11523-018-0571-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,24]]},"assertion":[{"value":"24 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Matt Shirley is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}